Replimune Group Stock Today
| REPL Stock | USD 14.93 3.88 35.11% |
Performance10 of 100
| Odds Of DistressLess than 25
|
Replimune is selling for 14.93 as of the 25th of November 2024. This is a 35.11 percent increase since the beginning of the trading day. The stock's lowest day price was 13.13. Replimune has about a 25 % chance of experiencing some form of financial distress in the next two years of operation and had a somewhat ok performance during the last 90 days. Equity ratings for Replimune Group are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of June 2023 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 20th of July 2018 | Category Healthcare | Classification Health Care |
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. Replimune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 68.42 M outstanding shares of which 7.05 M shares are at this time shorted by private and institutional investors with about 11.52 trading days to cover. More on Replimune Group
Moving against Replimune Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Replimune Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO, Director | Robert Coffin | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsReplimune can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Replimune's financial leverage. It provides some insight into what part of Replimune's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Replimune Group (REPL) is traded on NASDAQ Exchange in USA. It is located in 500 Unicorn Park Drive, Woburn, MA, United States, 01801 and employs 331 people. Replimune is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.02 B. Replimune Group conducts business under Biotechnology sector and is part of Health Care industry. The entity has 68.42 M outstanding shares of which 7.05 M shares are at this time shorted by private and institutional investors with about 11.52 trading days to cover.
Replimune Group currently holds about 395.08 M in cash with (185.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.01.
Check Replimune Probability Of Bankruptcy
Ownership AllocationThe majority of Replimune Group outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Replimune Group to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Replimune. Please pay attention to any change in the institutional holdings of Replimune Group as this could imply that something significant has changed or is about to change at the company.
Check Replimune Ownership Details
Replimune Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-09-30 | 1.4 M | |
| Tang Capital Management Llc | 2024-09-30 | 1.2 M | |
| State Street Corp | 2024-06-30 | 1.2 M | |
| Rtw Investments, Llc | 2024-06-30 | 1.1 M | |
| D. E. Shaw & Co Lp | 2024-09-30 | 867.7 K | |
| Ecor1 Capital, Llc | 2024-09-30 | 850.3 K | |
| Goldman Sachs Group Inc | 2024-06-30 | 666.1 K | |
| Fmr Inc | 2024-09-30 | 626.4 K | |
| Schonfeld Strategic Advisors Llc | 2024-09-30 | 572.2 K | |
| Baker Bros Advisors Lp | 2024-09-30 | 11 M | |
| T. Rowe Price Associates, Inc. | 2024-06-30 | 9.2 M |
Replimune Historical Income Statement
Replimune Stock Against Markets
Replimune Corporate Management
| Sushil Patel | Chief Officer | Profile | |
| Colin Love | Chief Officer | Profile | |
| Christopher Sarchi | Chief Officer | Profile | |
| Tanya MS | Chief Officer | Profile | |
| Pamela Esposito | Chief Business Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Replimune Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. If investors know Replimune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Replimune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.04) | Return On Assets (0.27) | Return On Equity (0.50) |
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Replimune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Replimune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Replimune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.